Patent: 9,995,753
✉ Email this page to a colleague
Summary for Patent: 9,995,753
Title: | Anti-pembrolizumab antibodies |
Abstract: | The present invention provides antibodies and antigen-binding fragments thereof that bind to the antibody pembrolizumab (pembrolizumab). These antibodies are useful, for example, for use as positive controls in assays for detecting the presence of anti-drug antibodies in a sample, e.g., the blood of a patient who has been administered pembrolizumab. |
Inventor(s): | Loo; LiNa (Monroe, NJ), Shi; Shuangping (Mountain Lakes, NJ) |
Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
Application Number: | 15/274,330 |
Patent Claims: | see list of patent claims |
Details for Patent 9,995,753
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-09-25 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-09-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |